BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35590107)

  • 1. Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.
    Bean GR; Najjar S; Shin SJ; Hosfield EM; Caswell-Jin JL; Urisman A; Jones KD; Chen YY; Krings G
    Mod Pathol; 2022 Oct; 35(10):1349-1361. PubMed ID: 35590107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Characterization of Neuroendocrine Carcinomas of the Endometrium: Representation in All 4 TCGA Groups.
    Howitt BE; Dong F; Vivero M; Shah V; Lindeman N; Schoolmeester JK; Baltay M; MacConaill L; Sholl LM; Nucci MR; McCluggage WG
    Am J Surg Pathol; 2020 Nov; 44(11):1541-1548. PubMed ID: 32773531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining triple-negative breast cancer with neuroendocrine differentiation (TNBC-NED).
    Hacking SM; Yakirevich E; Wang Y
    J Pathol Clin Res; 2023 Jul; 9(4):313-321. PubMed ID: 37082801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
    Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
    J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center.
    Shafi S; Hu Y; Parwani AV; Ding Q; Li Z
    Breast Cancer Res Treat; 2022 Dec; 196(3):463-469. PubMed ID: 36260193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
    Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
    Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. POU2F3-Expressing Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma Show Morphologic and Phenotypic Overlap.
    Jimbo N; Ohbayashi C; Takeda M; Fujii T; Mitsui S; Tsukamoto R; Tanaka Y; Itoh T; Maniwa Y
    Am J Surg Pathol; 2024 Jan; 48(1):4-15. PubMed ID: 37904277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
    Rehman S; Crow J; Revell PA
    Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas.
    Wang H; Yan L; Zhu Y; Sun W; Yang X; Liu X; Chi K; Huang X; Zhou L; Lin D
    Hum Pathol; 2023 Dec; 142():81-89. PubMed ID: 37742943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of p53 and Rb reveal subtypes of gastric neuroendocrine carcinoma with distinct prognosis.
    Xing J; Chen J; You T; Sun Z; Lu T; Cheng Y; Wu H; Bai C
    J Neuroendocrinol; 2023 Apr; 35(4):e13257. PubMed ID: 36964649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.
    Yachida S; Vakiani E; White CM; Zhong Y; Saunders T; Morgan R; de Wilde RF; Maitra A; Hicks J; Demarzo AM; Shi C; Sharma R; Laheru D; Edil BH; Wolfgang CL; Schulick RD; Hruban RH; Tang LH; Klimstra DS; Iacobuzio-Donahue CA
    Am J Surg Pathol; 2012 Feb; 36(2):173-84. PubMed ID: 22251937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary large-cell neuroendocrine carcinoma of the parotid gland: immunohistochemical and molecular analysis of two cases.
    Nagao T; Sugano I; Ishida Y; Tajima Y; Munakata S; Asoh A; Yamazaki K; Muto H; Konno A; Kondo Y; Nagao K
    Mod Pathol; 2000 May; 13(5):554-61. PubMed ID: 10824928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
    Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC
    Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
    Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
    Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
    Hadoux J; Kanaan C; Durand A; Hescot S; Hautefeuille V; Cadiot G; Tauveron I; Laboureau S; Do Cao C; Walter T; Petorin C; Blanchet O; Jannin A; Gu C; Faron M; Leteurtre E; Rousselet MC; Zakeyh JJ; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Ducreux M; Scoazec JY; Baudin E
    Eur J Cancer; 2021 Jul; 152():100-115. PubMed ID: 34090142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.
    Pang JB; Savas P; Fellowes AP; Mir Arnau G; Kader T; Vedururu R; Hewitt C; Takano EA; Byrne DJ; Choong DY; Millar EK; Lee CS; O'Toole SA; Lakhani SR; Cummings MC; Mann GB; Campbell IG; Dobrovic A; Loi S; Gorringe KL; Fox SB
    Mod Pathol; 2017 Jul; 30(7):952-963. PubMed ID: 28338653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast.
    Yang L; Roy M; Lin H; Shen Y; Albarracin C; Huo L; Chen H; Wei B; Bedrosian I; Bu H; Wu Y
    Breast Cancer Res Treat; 2021 Apr; 186(2):403-415. PubMed ID: 33528758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
    Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
    Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.